Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1401Other hematologic neoplasm 431Myeloid 34Plasma cell 29Sarcoma 27Dermatologic 15CNS 12Classical hematology 9Tumor-Agnostic 4Thoracic 4Breast 4Head & Neck 3Genitourinary 3Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Other neoplasm 1Other 1

Conditions

Pancreatic Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 1435Fluorouracil 1316Capecitabine 1112Gemcitabine 1054Leucovorin 935Bevacizumab 845Irinotecan 827Cisplatin 673Radiotherapy 559Cetuximab 481pembrolizumab 435Paclitaxel 400Drug Therapy 358Nivolumab 349130-nm albumin-bound paclitaxel 326Docetaxel 289Sorafenib 288S 1 (combination) 278Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 256lenvatinib 222sintilimab 218tislelizumab 213durvalumab 211regorafenib 208Radiosurgery 204Magnetic Resonance Spectroscopy 203apatinib 202Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rituximab × Gastrointestinal × Clear all
NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00001805 2008-03-04

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡